Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation

Christopher Mezias, Nolwen Rey, Patrik Brundin, Ashish Raj

PII: S0969-9961(19)30298-0
DOI: https://doi.org/10.1016/j.nbd.2019.104623
Reference: YNBDI 104623
To appear in: Neurobiology of Disease

Received date: 28 June 2019
Revised date: 5 September 2019
Accepted date: 23 September 2019

Please cite this article as: C. Mezias, N. Rey, P. Brundin, et al., Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation, Neurobiology of Disease(2018), https://doi.org/10.1016/j.nbd.2019.104623

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2018 Published by Elsevier.
Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: involvement of retrograde and anterograde axonal propagation

Christopher Mezias\textsuperscript{1,2,*}, Nolwen Rey\textsuperscript{4,*}, Patrik Brundin\textsuperscript{4,+}, Ashish Raj\textsuperscript{2,3,+}

* Indicates these authors contributed equally to this work and are co-first authors

+ Indicates these authors equally supervised this work and are co-last authors

\textsuperscript{1} Weill Cornell Medicine of Cornell University, Department of Neuroscience, New York, NY, 10065, USA

\textsuperscript{2} Weill Cornell Medicine of Cornell University, Department of Radiology, New York, NY, 10065, USA

\textsuperscript{3} University of California—San Francisco, Department of Biomedical Imaging

\textsuperscript{4} Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, 49503, USA

* Corresponding author: Christopher Mezias

Keywords: \(\alpha\)-synuclein, Lewy pathology, Parkinson’s Disease, Dementia with Lewy Bodies, prion-like propagation, mouse connectome, network diffusion models, graph theory
Highlights

- Mathematically modeling αsyn spread along fiber tracts recreates inclusions patterns
- Modeled retrograde (post-to-presynaptic) spread best recreates early inclusions patterns
- Modeled anterograde (pre-to-postsynaptic) spread better fits later inclusions patterns
- Overall results indicate a potential directional switch in αsyn spread over time
- All above results are consistent across multiple, independently collected, datasets

Abstract

In Parkinson’s disease, some of the first alpha-synuclein aggregates appear in the olfactory system and the dorsal motor nucleus of the vagus nerve before spreading to connected brain regions. We previously demonstrated that injection of alpha-synuclein fibrils unilaterally into the olfactory bulb of wild type mice leads to widespread synucleinopathy in brain regions directly and indirectly connected to the injection site, consistently, over the course of periods longer than 6 months. Our previously reported observations support the idea that alpha-synuclein inclusions propagates between brain region through neuronal networks. In the present study, we further defined the pattern of propagation of alpha-synuclein inclusions and developed a mathematical model based on known mouse brain connectivity. Using this model, we first predicted the pattern of alpha-synuclein inclusions propagation following an injection of fibrils into the olfactory bulb. We then analyzed the fitting of these predictions to our published histological data. Our results demonstrate that the pattern of propagation we observed in vivo is consistent with axonal transport of alpha-synuclein aggregate seeds, followed by transsynaptic transmission. By contrast, simple diffusion of alpha-synuclein fits very poorly our in vivo data. We also found that the spread of alpha-synuclein inclusions appeared to primarily follow neural connections retrogradely until 9 months after injection into the olfactory bulb. Thereafter, the pattern of spreading was consistent with anterograde propagation mathematical models. Finally, we applied our mathematical model to a different, previously published, dataset involving alpha-synuclein...
fibril injections into the striatum, instead of the olfactory bulb. We found that the mathematical model accurately predicts the reported progressive increase in alpha-synuclein neuropathology also in that paradigm. In conclusion, our findings support that the progressive spread of alpha-synuclein inclusions after injection of protein fibrils follows neural networks in the mouse connectome.

Introduction

Parkinson’s disease is characterized neuropathologically both by death of substantia nigra dopamine neurons and the progressive accumulation of pathological inclusions in widespread parts of the nervous system [19]. These inclusions, named Lewy bodies and Lewy neurites, are mainly composed of misfolded alpha-synuclein (αsyn) [18; 19] and they engage an increasing number of brain regions as the disease progresses over several years. This spreading of Lewy pathology in the brain follows a stereotypical pattern and has been suggested to first start in the olfactory system and the dorsal motor nucleus of the vagus [4; 5; 6; 7; 8; 15]. The brain regions that sequentially develop Lewy pathology in PD are all interconnected, an observation that provided some of the scientific premise for the hypothesis that αsyn aggregates can propagate from one neuron to another via neural connections [1; 4; 10; 21].

Extensive work using in vitro models has subsequently demonstrated that misfolded αsyn can act as a template and impose its aberrant conformation to native αsyn, and that the seeds of misfolded αsyn can be released and taken up by neighboring cells that in turn develop αsyn inclusions [11; 20; 40; 44]. Thus, misfolded αsyn itself could be a vector of propagation and could underlie a propagation of synucleinopathy between brain regions in humans [11; 37]. To address this hypothesis, several groups have tested the seeding and prion-like spreading of pathological αsyn in vivo [13; 14; 37]. Intracerebral or peripheral injection of recombinant αsyn
fibrils or αsyn aggregates derived from brain lysates from post-mortem patients with synucleinopathy can induce αsyn aggregation in both animals overexpressing αsyn and in wild type animals [11; 14; 24; 32; 37].

Several previously published studies have focused on defining the development of abnormal αsyn inclusions following injections into the striatum or in the substantia nigra, which exhibit synucleinopathy only in advanced PD. By contrast, recent reports from our group have focused on triggering synucleinopathy in the olfactory bulb because it is believed to be one of the first brain regions affected in PD [34; 35; 36; 37]. By unilateral stereotaxic injection of recombinant αsyn fibrils into the olfactory bulb of wild type mice, we have demonstrated αsyn aggregation is initially triggered at the site of injection and then it progressively spreads sequentially to interconnected brain regions [34; 36]. Our published observations strongly suggest propagation via a neuronal network, but they do not completely rule out other spreading routes such as local diffusion, or migration of glia containing seeds [33]. Indeed, some reviews of the literature to date on αsyn pathology spread question whether the propagate via neural connectivity [40] and suggest that given inconsistencies in the transsynaptic spread literature, perhaps cell-type specific explanations might provide a better explanation [42] for observed pathology proliferation patterns.

To further define the anatomical patterns and dynamics of the spread of αsyn inclusions, and thereby gain greater insight into the role of neural connections, here we reanalyze our own data with a specific focus on network transmission of inclusions. For this purpose, we use our recently developed mathematical model called Directional Network Transmission (DNT) [26; 27], which we have previously demonstrated can predict tau pathology transmission in the mouse brain, but does not well represent αβ progression. In turn, this model was based on our original
Network Diffusion model of human degenerative progression [30; 31], which was successful in recapitulating the spatiotemporal pattern of atrophy in human dementia. These mathematical models provide a useful new way of testing hypotheses regarding network transmission since they do not rely on correlative evidence from isolated regions or fiber projections, but can be applied to the entire brain connectome at once. This addresses a gap in the current research regarding the relationship between neural connectivity and αsyn spread, as there is presently a lack of studies elucidating the relationship between the whole brain connectome and αsyn inclusions patterns [42]. In addition, while both anterograde and retrograde transmission of αsyn have been observed in cell culture models [16; 52] the issue of directional bias in αsyn pathology transmission remains controversial [3; 17; 46]. Accordingly, we undertook the current study to investigate whether the longitudinal evolution of αsyn inclusions and direction of propagation can be predicted by directional trans-neuronal network transmission based on the anatomic network connectivity (or “connectome”) of the mouse.

Using the DNT model and mouse connectome, we studied propagation of αsyn inclusions from the olfactory bulb over time and analyzed the fitting of these predictions to our published in vivo data [34; 36]. Our work demonstrates that the model of propagation via neuronal networks fits the best with our published in vivo observations. Our work also confirms that a spatial diffusion model fits very poorly with our in vivo data. We also found that a retrograde spreading of inclusions during the first months after injection of αsyn fibrils followed by the involvement of anterograde progression explains with the pattern of inclusions propagation we observe after triggering synucleinopathy in the olfactory bulb. In addition, we applied our DNT model to two additional models of propagation: our dataset based on striatal
injections of PFFs [12] and a published dataset from a model of intra-nigral injection of alpha-synuclein fibrils [25].

Methods

Our previously published work supported the idea that αsyn pathology propagates along axonal pathways, but we could only provide correlative evidence. Therefore, we further analyzed the propagation of αsyn-inclusions from the olfactory bulb in wild type mice. To this end, we developed a model of the theoretical pattern of propagation based on different propagation mechanisms (spatial proximity-based propagation by diffusion; connectivity-based propagation along fiber tracts in anterograde or retrograde directions). We implemented this theoretical model using published data on the mouse connectivity network and compared the fitting of our theoretical models to our in vivo observations.

Mouse Brain Connectivity Network. We use data from the Allen Institute for Brain Science’s Mouse Connectivity Atlas (MCA) to create the mouse connectivity network. This network is derived from viral tracing studies and contains fully directional connectivity intensity information from 426 regions across both hemispheres; more information on the MCA can be found at the Allen Institute’s website and in the citation [28]. The network we use here can be obtained either on the Allen Institute’s website in the ‘Mouse Connectivity Atlas’ section or in Supplemental Materials attachment #4 from the above cited paper [28].

Mouse experiments and data collection for original synucleinopathy dataset (propagation of synucleinopathy from the olfactory bulb). We injected C57/Bl6 wild type mice unilaterally into
the olfactory bulb with αsyn pre-formed fibrils (PFFs) made of recombinant wild-type mouse αsyn PFFs (mPFFs) or wild-type human αsyn PFFs (huPFFs). The mice were sacrificed via transcardial perfusion with 4% paraformaldehyde in groups at either 1, 3, 6, 9, 12, or 18 months post-injection. The entire brains were sectioned coronally on a microtome into 30 µm thick sections in 8 series. Free-floating sections were stored in cryoprotectant until use. We stained every 8th section of the entire brain with Ab51253 (Abcam) for αsyn phosphorylated on Serine 129, a marker of pathological αsyn [2; 33; 34; 36]. Endogenous peroxidase were blocked by incubation with 3% H2O2 for 20 min. Sections were then blocked in 10% normal goat serum, 0.3% triton x100, 0.4% Bovine serum albumin; followed by overnight incubation with rabbit anti psr129 antibody (1/10000 in 2% normal goat serum, 0.3% triton X100). We incubated the sections with secondary antibody goat anti-rabbit biotinylated (1:500, Vector lab) in blocking solution. Sections were then incubated for 1hour in ABC (ABC Kit, Vector lab) and revealed using DAB kit (Vector lab).

These sections were blind coded and were analyzed at x20 using Nikon eclipse Ni-U microscope. We semi-quantitatively rated αsyn inclusions on a 0-4 scale (one score per brain region) based on relative abundance of psr129 inclusions: 0=no aggregates; 1=sparse: very few neurites, max 1 soma; 2=mild inclusions; 3=dense inclusions; 4=very dense inclusions) for 4 mice per group at 1 month post-injection, 4 mPFF and 3 huPFF injected mice at 3 months, 5 mPFF and 4 huPFF injected mice at 6 months, 3 mPFF and 5 huPFF injected mice at 9 months, 7 mPFF and 5 huPFF injected mice at 12 months, and 5 huPFF and 3 mPFF injected mice at 18 months. Mouse brain regions were manually identified using the Paxinos and Franklin mouse brain atlas [29]. The list of the brain regions where αsyn inclusions were detected can be found in the original publications [34; 36]. Importantly, the staining conditions used would detect only
dense pser129-positive inclusions and we have shown previously [34; 36] that these inclusions
shared the markers for pathological αsyn aggregates (colocalization with p62, ubiquitin and
Thioflavin-S positive). During the scoring, any weak homogenously stained cell bodies were
excluded from analysis to semi-quantify only dense inclusions.

Further details on mouse experiment methodology for this data can be found in the same
original publications [34; 36]. It should be noted that data from timepoints up to 12 months post-
injection [36] and the dataset obtained at 18 months post-injection [34] were quantified
separately and some subregions were grouped differently. Thus, the datasets were not directly
comparable, and so r, Δr, and p-values cannot be directly compared. Instead we observe that the
pattern of results produced by comparing the 18-month dataset with our modeled predictions
remains consistent with the suggested pattern of increasingly heavy involvement of anterograde
transit along fiber tracts as a driver of αsyn inclusions propagation. We still include the 18-
month data with other quantified timepoints in Figure 5 as this is meant to be illustrative of the
pattern of results we see. Our more in-depth analyses separate the data up to 12-months (Figures
2 & 3) and at 18-months (Figure 4) post-injection into different figures.

**Mouse experiments and data collection for original dataset from intrastriatal injections of
PFFs.** For striatal injections, human alpha-synuclein was purified and assembled into PFFs in
house following previously published protocols [23; 50]. PFFs were thawed and sonicated as
previously published [34; 36]. 4 week old OF1-Swiss mice were injected stereotactically 2ul of
PFFs unilaterally into the dorsal striatum as previously described (striatum coordinates from
bregma: AP; +0.2mm, ML: -2.0mm, DV: -2.6mm). Mice were euthanized 8 weeks post injection
by deep anesthesia with sodium pentobarbital and perfused transcardially with 0.9% saline, then
4% paraformaldehyde (PFA) in phosphate buffer. We collected the brains and post-fixed them for 24 hours in 4% PFA. Brains were then stored in 30% sucrose in phosphate buffer at 4 °C until use. Brains were sectioned coronally into 40 um thick sections on a freezing microtome. Free floated sections were stored in cryoprotectant.

The following staining protocol and semiquantitative analyses were employed: Pser129 inclusions was semi-quantified across almost 40 regions, at one timepoint 8 weeks post-injection with in house recombinant human PFFs. The semi-quantification in this study was based on immunohistochemistry and followed the same procedure for converting IHC signal to semi-quant as in [34; 36]. While this dataset is only cross-sectional rather than longitudinal, as it only contains one timepoint, it contains data from each individual mouse. With this dataset we accordingly assessed whether there was an identifiable directional predilection, according to our DNT modeling, in αsyn spread. The citation for this dataset can be found in [12].

**Mouse synucleinopathy datasets obtained from other sources (intra-nigral injections of fibrils).** To further investigate the propagation of abnormal inclusions in regards to theoretical propagation along axonal network, we chose to apply our connectivity model to another published dataset: Masuda-Suzukake, et al., 2013 [25]. Similar to our previous work [34; 36], this study used immunohistochemistry as the basis for all quantifications or semi-quantifications and wild-type mice. In the study by Masuda-Suzukake et al., [25] mice were injected into the substantia nigra with recombinant αsyn fibrils, and at least 40 separate brain regions were quantified for αsyn inclusions. The investigators semi-quantitatively assessed αsyn pathology by grading regional severity out to 15 months post-injection using 3 months and 6 months as intermediary timepoints.
**Connectivity metrics, NT, and DNT.** Connectivity metrics are calculated based on the topology of the mouse brain network derived from the MCA, where connectivity is represented as “outgoing” along the rows and “incoming” along the columns [28]. We generated a directed and weighted connectivity measure with seed regions by summing the weighted row-wise or column-wise values in the MCA at the seed nodes. We could then correlate each selected region’s measured αsyn inclusions with its weighted connectivity, in both anterograde and retrograde directions, with the seed nodes in each study. Further information on using the MCA and its connectivity data for graph analyses can be found at the original citation [28] and in our prior paper using this atlas [26].

NT and DNT modeling is similarly dependent on the MCA in this study, and on regional graph adjacency to the seed nodes or nodes already containing inclusions. We first calculate the Normalized Adjacency or Laplacian Matrix, $L$, given by the equation below:

\[
L = I - D_R^{-1/2} \cdot C \cdot D_C^{-1/2}
\]

where $C$ is the connectivity matrix from the MCA, $I$ is the identity matrix, and $D_R$ and $D_C$ are the row and column wise diagonal matrices from the MCA. Previous graph theoretic work has characterized diffusion over a network from defined seed points and has been shown to be predictive for both volumetric loss [16; 30] and metabolic dysfunction [31] in patients with AD or other tauopathic dementia, as well as for mouse models of tauopathy and amyloidopathy [26; 27]:

\[
X_{NT}(t) = e^{-\beta t L} \cdot X(0) \quad (1)
\]

Here $L$ is the Laplacian Matrix, $\beta t$ is a constant representing diffusion time determined by when it maximizes $\Delta R$, which is the change in R-value from $\beta t = 0$ to maximum, $X(0)$ is a vector with
The number of nodes length representing seeding, and \( X(t) \) is a vector with \( n \) number of nodes length representing the final pattern of network diffusion. Further information on the derivation of the above equation and graph diffusion modeling can be found at the aforementioned citations.

In the present study, we use a modified version of the above NT model equation so that we could both capture the directionality information from the MCA allowing us to represent synucleinopathy as not only a process of spread but also of accumulation, analogous to a prion-like disorder. We captured the directionality information from the MCA by calculating different networks for each direction, where \( C \) represents the standard connectivity network, \( C^T \) represents the network in the retrograde direction, and the summed connectivity of both, \( C + C^T \), represents the undirected network derived from the MCA. Here we use an integrative or summative approach to capture accumulation and so the equation can be represented in two manners:

\[
X_{DNT}(i) = e^{-\beta t} \cdot X(i-1) + X(i-1)
\]  

More information on the mathematics behind this approach can be found in our previous work [26; 27; 31]. The Spatial diffusion model (SPD) uses the same Laplacian and model equation, (2), from above; the difference between NT or DNT models and the SPD model is that the SPD model, as its network, instead utilizes the Cartesian distances, in voxels, between the centers of mass of any given region pair, rather than their axonal connectivity.

**Data analyses.** All analyses performed were a variant of a standard linear regression using natural log transformed regressions due to empirical pathology and predicted values being best fit by exponential distributions. As in our previous studies [26; 27], we assessed each model by considering the Pearson’s R-statistic of the correlation between the (D)NT model, evaluated at
all model times $\beta_t$, and the empirical regional distribution of synucleinopathy concentration from the mouse brains. The model time $\beta_t$ is not directly knowable form the model, and hence we chose to record the maximum correlation achieved by the model at all possible model times. We collected two quantities at the peak correlation: the Pearson R-value, as well as the $\Delta R$-value, here defined as the difference between the maximum R-value, and the R-value achieved by the model at $\beta_t = 0$, i.e. the synuclein inclusions seed pattern. The latter is a relevant measure of model performance, since it indicates how much additional value is added by network transmission beyond the initial seeding pattern. To determine directional bias, we subtracted retrograde DNT $\Delta R$-values from anterograde DNT $\Delta R$-values, as given by Eqn. (3):

$$Bias = \Delta R_{ANT} - \Delta R_{RET}$$

(3)

A calculated bias value of 0 using Eqn. (3) would indicate no bias, a value >0 would indicate a bias in the anterograde direction, and a value <0 would indicate a bias in the retrograde direction. To test for the effects of progression time on directional bias in $\alpha$syn propagation we correlated each measured timepoint’s retrograde and anterograde bias, across all studies, and correlated that with the time of measurement (in months) after study initiation. We also correlated the bias difference scores, as calculated above, across timepoints. Because we present 24 total correlations, when assessing for significance, we corrected the $\alpha$-value threshold for significance, originally at $p < 0.05$, by dividing it by 24 to yield a significance cutoff at $p < 0.002$. We analyzed the striatal injection dataset from [12] using two-sample t-tests to compare r-values across all data using anterograde versus retrograde biased DNT. All statistical analyses were performed using MatLab unless explicitly stated otherwise.

Results
To investigate the propagation of synucleinopathy throughout the brain and define in which direction trans-axonal propagation occurs, we compared the data collected in our in vivo model to the theoretical propagation pattern based on regular axonal transmission (NT), retrograde axonal transmission (DNT-ant), anterograde axonal transmission (DNT-ret) and Spatial Diffusion (SPD), as calculated using Equations 1, 2, evaluated on the (426 x 426) connectivity matrix obtained from the Allen Institute for Brain Science’s Mouse Connectivity Atlas (MCA). First, we aimed to go beyond the kind of correlative analysis of isolated or selected brain regions reported in previous studies, and instead wanted to create a model-based mathematical validation of the network transmission hypothesis on the entire brain network. Second, we aimed to quantitatively establish whether directional bias is observed in serial inclusions data and can explain patterns of synucleinopathy propagation. Figures 1a & b illustrate directional spreading of inclusions and the DNT model, and Figure 1c shows parameter fitting across βt-values using the DNT model, as well as predictive and non-predictive model curves. In Figure 1d, we provide an example of the anatomical illustrations we use with the DNT model, along with a universal legend for all such figure panels.

**Interregional α-syn propagation initially mirrors retrograde direction spread along fiber tracts, but increasingly involves anterograde direction transit as time elapses.** Using equation (2) and a seed signal placed at the injection site in the olfactory bulb, we evolved the DNT model at all model “diffusion times” βt. We first selected 3 and 12 months as timepoints representing respectively short and long amounts of time post-injection, and then assessed interregional αsyn inclusions propagation. The peak R-value between the model evaluated at all model times βt, and empirical regional αsyn inclusions data at 3 months post-injection, both retrograde DNT, R =
0.51, p < 0.01 and undirected NT, R = 0.44, p < 0.01, trend towards significantly matching the data of mice injected with mPFFs (Figure 2a-b). We anatomically illustrate the data and our retrograde DNT (DNT-Ret) model’s predictions in Figure 2c using a “glass brain” rendering whereby spheres represent brain regions and their size is proportional to the regional value of interest. Anterograde DNT (DNT-Ant) and Spatial diffusion (SPD) models do not significantly recreate empirical inclusion pattern at 3 months post-injection. However, by 12 months following αsyn fibrils injection, anterograde DNT, R = 0.63, p < 0.002, along with retrograde DNT, R = 0.60, p < 0.002, and undirected NT, R = 0.68, p < 0.002 (Figure 2d-e) all produce significant recreations of empirical regional αsyn inclusions data in mice injected with mPFFs. We anatomically illustrate our anterograde DNT model’s regional inclusions predictions and empirical data in Figure 2f. The SPD model continues to fail to produce any pattern that significantly matches empirical data.

We observe a remarkably similar pattern in our datasets between injection at 3 and 12-months post injection in mice injected with huPFFs. Retrograde DNT, R = 0.65, p < 0.002, and undirected NT, R = 0.59, p < 0.002 significantly recreate empirical regional αsyn inclusions patterns at 3-months post-injection, while anterograde DNT does not (Figure 3a-b). We anatomically illustrate the strong match between retrograde DNT and empirical data in Figure 3c. However, by 12-months post-injection anterograde DNT, R = 0.72, p < 0.002, significantly, and most faithfully, recreates empirical regional patterns of αsyn inclusions (Figure 3d-e).

Retrograde DNT, R = 0.57, p < 0.01, trends toward, and undirected NT, R = 0.67, p < 0.002 significantly, recreate empirical inclusions patterns (Figure 3d-e). We anatomically illustrate the data and the anterograde DNT model’s recreation in Figure 3f. The SPD model does not recreate spatiotemporal αsyn inclusions patterns in mice injected with huPFFs.
We further analyzed the 18-month post-injection data and observed the same phenomenon of implied heavy involvement of anterograde direction fiber tract transit in mice injected with both mPFFs and huPFFs. As referred to in our note above, the $R$, $\Delta R$, and p-values at 18 months are not directly comparable with those from the other timepoints in our dataset, so we analyze and present the 18-months data separately. We found that anterograde DNT produces a significant, and the strongest, recreation of regional inclusions patterns in both mice injected with huPFFs, $R = 0.64$, $p < 0.002$ (Figure 4a-b) and mice injected with mPFFs, $R = 0.70$, $p < 0.002$ (Figure 4d-e), compared to retrograde DNT, non-directional NT or spatial diffusion. Data at 18-months post-injection from both mice injected with huPFFs and mPFFs also trends towards or does produce significant, albeit not as faithful, recreations by retrograde DNT, $R = 0.49$, $p < 0.01$ (huPFFs), $R = 0.60$, $p < 0.002$ (mPFFs), and undirected NT, $R = 0.55$, $p < 0.01$ (huPFFs), $R = 0.63$, $p < 0.002$ (mPFFs) (Figures 4a-b & 4d-e). We anatomically illustrate data as well as predictions from our anterograde and retrograde DNT models in Figure 4c (huPFFs) and Figure 4f (mPFFs). We again find the consistent pattern, across injectate types, of implied heavy involvement of anterograde direction fiber tract travel as a driver of $\alpha$syn pathology spread.

We next computed $\Delta R$-values as described in Data Analysis subsection of Methods. We repeated this for anterograde, retrograde and bidirectional DNT models, as well as the non-network spatial diffusion model. We repeated above analysis by comparing the model against each individual time point of the empirical mouse data. We found that the DNT model of retrograde spread of $\alpha$syn along fiber tracts, as modeled by (DNT-Ret), fits better the in vivo $\alpha$syn propagation pattern, as measured by $\Delta R$-value against empirical $\alpha$syn inclusion data at 3, 6, and 9 months post-injection than does anterograde spread, modeled by (DNT-Ant.). However, by 12 months (the last numerically directly comparable timepoint in these data – please refer to
material and methods), this pattern is reversed and anterograde DNT gives a better fit for spatiotemporal αsyn inclusions propagation. Furthermore, despite being slightly different in terms of number and location of regions quantified, the data obtained from 18-months post-injection shows the best fits with modeled synucleinopathy spread proceeding in the anterograde, as opposed to retrograde, direction, consistent with the 12-months results. This result is consistent regardless of whether mice were initially injected with mouse- (Figure 5a) or human- (Figure 5b) PFFs. Furthermore, bias towards anterograde synucleinopathy propagation, as measured by anterograde DNT ΔR-value minus retrograde DNT ΔR-value, consistently increases over time in both human and mouse PFF datasets (Figure 5c).

Data using other injection sites suggests a similar pattern of early retrograde and later anterograde spread involvement in interregional αsyn propagation. We first directly test whether there might be an initial retrograde bias in early post-injection αsyn inclusions, using the dataset obtained from the Masuda-Suzukake, et al., 2013 [25] publication and another dataset from one of our labs [12]. We find that in the dataset from [25], at both 3 and 6 months post-injection, akin with similar timepoints post-injection from our own dataset (see above), there is a retrograde bias in how well DNT fits αsyn inclusions data. We further find that, in other data from one of our labs [12], the spatial pattern of αsyn inclusions at only 8 weeks post-injection with fibrils, is best fit by retrograde DNT, p < 0.002, (Figure 6a) using a two-sample t-test. Akin to results obtained using our own datasets, there is however a switch to a finding of anterograde bias in how well DNT fits αsyn pathology data by 15 months post-injection (Figure 6b). We subsequently used the data from [25], to create an example illustration of the phenomenon of implied heavy and increasing anterograde direction fiber tract transit involvement in
interregional \( \alpha \text{syn} \) propagation, as \( \Delta R \)-values for retrograde DNT are strong by 3 and 6-months post-injection, but anterograde DNT \( \Delta R \)-values are even higher than those of retrograde DNT by 15 months post-injection (Figure 6c). We anatomically illustrate our results using data from the Masuda-Suzukake, et al., 2013, study in Figure 6d. More information on the dataset from [25] and the data from Patrik Brundin’s lab used here can be obtained in the **Mouse synucleinopathy dataset obtained from published source** subsection of the **Methods** section. These results and their implications are further explored in the **Discussion**.

**Discussion**

Our results confirm that \( \alpha \text{syn inclusions} \) are likely to spread along axons and transsynaptically after triggering synucleinopathy by localized injection of \( \alpha \text{syn} \) fibrils. We also observed that both anterograde and retrograde \( \alpha \text{syn} \) propagation are possible. Our results suggest that \( \alpha \text{syn inclusions} \) spreading is directionally biased with a predominance of retrograde propagation first, and that the directional bias of \( \alpha \text{syn} \) pathology propagation changes over time. Specifically, until 9 months post injection, a propagation model involving retrograde transport reproduces the pattern we observed in our animal experiments. In a second phase, 12 months post injection and later, a combination of retrograde and anterograde propagation explains the spatial pattern observed *in vivo*. A time-dependent directional bias can help explain why in human synucleinopathies some brain regions that are strongly connected to an affected brain area are spared early on, but not later, in the disease course.

We found that our mathematical model of anatomical spreading of \( \alpha \text{syn inclusions} \) applied well to both our own data from a mouse model involving \( \alpha \text{syn} \) PFFs injection into the olfactory bulb [34; 36], as well as in mice where \( \alpha \text{syn} \) fibrils or PFFs were injected into either
the Substantia nigra [25] or striatum [12]. While we consistently observed a preferred retrograde spread early and anterograde spread late after injection of fibrils/ PFFs, we do imply that the directional switch we find here is a general rule. It is possible that the particular conformation of the initial seed of αsyn aggregates (i.e. specific αsyn “strains”) and the anatomical region where the first seeding event takes place (e.g. olfactory bulb versus substantia nigra) will significantly influence the direction (antero- or retrograde) of spread. We discuss the relevance of this to both αsyn pathology in general and with regards to specific synucleinopathies (e.g. PD, DLB) in subsections below.

Transsynaptic and fiber tract-based spread model replicates the αsyn inclusions spread observed in vivo. Axonal transport followed by transsynaptic spread have been proposed as the predominant mechanisms underlying αsyn pathology propagation between brain regions [1; 9; 10; 11; 14; 33; 40; 45]. Some studies have utilized cell cultures models [17; 52] that do not reflect the complexity of brain connectivity and also lack several of its cellular components (e.g. different glia). Other researchers question the transsynaptic spread hypothesis entirely, arguing that the spread of αsyn pathology does not follow a synaptic connectivity rule [41; 42]. We explicitly test the transsynaptic and connectome based spread hypothesis using our current DNT model, with connectome data obtained from the Allen Brain Institute mesoscale mouse connectome [http://connectivity.brain-map.org; 28]. This atlas provides detailed anatomy of 426 different nodes (corresponding to brain regions), and their connections are based on extensive tracing experiments. The connectome takes into account the direction of transport of the tracers and the weight of the different connections. It is, therefore, a very powerful tool to investigate the theoretical patterns of propagation based on anterograde, retrograde or diffuse spreading of
pathological seeds. To use this connectome with our DNT modeling, we had to make several assumptions. We assumed that there are no brain-region specific biases in the transfer or uptake of their adenovirus tracer [28] and that uptake is therefore even, allowing for some noise, across all parts of the mouse brain. We also assumed that there is a directly proportional relationship between fluorescent signal from the viral tracer and the total number or volume of axonal tracts from the seeded to the signal region. As discussed in the ABI paper introducing the MCA [28], these assumptions are unlikely to be true across the board, but are likely accurate enough at the coarse parcellation of a brain into 426 regions. Importantly, making these assumptions allows our model to simulate spread over the entire connectome.

We demonstrate clear correspondence between regions most likely (based on neuronal connections) to exhibit pathology from the region where the initial seeding takes place (the olfactory bulb, substantia nigra, or striatum) and the regions that we found to contain αsyn inclusions in in vivo experiments [25; 34; 36] (Figures 2-5). To confirm that the fitting of the theoretical propagation pattern with the empirical in vivo data is not dependent on site of pathology-initiation, we analyzed previously published datasets using two different injection sites [25; 34; 36]. We found the same correspondence between our theoretical modeling of propagation and published data from [25] using with the substantia as initiation site. We further demonstrate retrograde DNT recreates spatial αsyn patterns [12] (Fig 6d). We also tested whether a pattern of spread based on spatial, rather than connectome proximity to the seed region, would recapitulate αsyn patterns, implying potential active or passive extracellular spread of pathogenic protein aggregates. This analysis showed that spatial diffusion is not a predictor of αsyn inclusions localization in the two datasets we examined (Figures 2-6), and provides further support for the transsynaptic αsyn pathology spread hypothesis.
Importantly, recently published work from Virginia L.Y. Lee’s group investigated also the spread of αsyn pathology through the mouse brain using connectome modeling [22]. In this study, the authors investigated the propagation of αsyn inclusions from several injection sites in a time window of 1 to 6 months post injection. In this study, inclusions were also detected with an antibody directed against hyperphosphorylated alpha-synuclein and stained sections were analyzed quantitatively in an automated way. The authors also implemented in their model the expression level of αsyn at the injection site. Despite different methods used, both our work and Henderson et al.’s demonstrate that early propagation is occurring preferentially in a retrograde direction, and that the preferential retrograde propagation is a generalized mechanism to all the brain regions each lab tested. In addition, the authors observed that the regional level of expression of αsyn influences strongly the vulnerability of a given brain region to develop αsyn inclusions. The study by Henderson et al explores only short injection delays (up to 6 months), and thus do not investigate the long delays post injections where we observed a switch to a preferential anterograde propagation direction after 9 months, both in our OB-injection dataset and in data from [25].

**Directional switching of αsyn propagation might explain divergent spatiotemporal pathology development patterns between patients.** One advantage of our paradigm is the possibility to test transregional spread along fiber tracts in both anterograde (pre-to-postsynaptic) and retrograde (post-to-presynaptic) directions. Interestingly, we found that both anterograde and retrograde directions can successfully recreate transregional αsyn inclusions spread, consistent with prior cell culture [17; 52] and in vivo [38; 47; 48] studies showing both anterograde and retrograde
transport of αsyn. In fact, our results suggest that the directional bias of αsyn spread may in fact change over time.

What cellular mechanisms might contribute to change biases in directional spread over time? Prior work on transsynaptic αsyn propagation suggests that spread through a neural network in an anterograde direction might involve release of exosomes into the synaptic cleft [40]. However, retrograde spread can also occur, via release into the synaptic cleft from dendrites or soma, and possibly enter the presynaptic side via tunneling nanotubes or even receptor mediated internalization [45]. For network spread to occur bidirectionally, both transsynaptic propagation and axonal transport/diffusion of αsyn must be bidirectional, assumptions that are supported by cell culture and microfluidic studies [39; 43; 49]. Interestingly, αsyn can interfere with the net directionality of axonal transport by its interaction with kinesin and dynein motors [39; 49], and thereby affect directional bias.

We speculate that biased spread influences spatiotemporal development of αsyn pathology and partly explains why some regions exhibit αsyn inclusions while others do not. The enteric nervous system and/or the olfactory system represent two possible locations where the accumulation of misfolded αsyn species overwhelm the cellular protein degradation mechanisms in PD and DLB. In PD, αsyn inclusions development in the central nervous system is generally first observed in dorsal motor nucleus of the vagus nerve (the origin of enteric nerves) and in olfactory areas such as the olfactory bulb and anterior olfactory nucleus [4; 5; 6; 7; 8; 15; 37; 45]. In DLB, αsyn aggregates are frequently seen in olfactory structures as well as limbic system [2].

Our work posits not only directional biases in αsyn spread, but a directional switch in these biases (Figures 2-6). αSyn can interact with both anterograde direction kinesin and
retrograde direction dynein axonal transport protein families [3]. Importantly, αsyn misfolding appears to decrease its anterograde transport by kinesin proteins, and increase its retrograde transport by dynein proteins [51] by at latest 8 weeks post-aggregation initiation. This could explain an early retrograde bias in αsyn propagation that shifts to either bidirectional or anterograde αsyn spread as αsyn inclusions progress. Because both the substantia nigra and olfactory areas have dense connections with the striatum [28], the relative sparsity of αsyn aggregates in the striatum in PD might be viewed as unexpected. However, if transsynaptic αsyn spread is predominantly in the retrograde direction early in disease course (Figures 2-6), we would indeed not expect early pronounced αsyn inclusions accumulation in the striatum because most of the connections between the injected olfactory bulb and the striatum are afferents to the striatum [28].

Assumptions and limitations. There are limitations of our model and of our datasets. First, our DNT modeling rely on several assumptions so we could model the spread over the entire connectome (we assumed that the uptake of adenovirus tracer is even in the brain, and assume that the tracers fluorescent signal is proportional to the volume of axonal tracts containing fluorescent signal). As mentioned earlier and as discussed in previous work [28], our assumptions are likely accurate enough for the parcellation in 426 brain regions we are using here.

In addition, the model does not consider region-specific factors that may influence the susceptibility of regions to become ‘infected’ by pathogenic αsyn. Therefore, our model does not consider region-specific factors which can influence an area’s susceptibility to develop inclusions, regardless of spread, a concern other recent work investigating αsyn inclusion spread
notes [22]. Our model also does not reflect that neurons might die, due to aggregates forming, in some brain regions, and therefore neither updates the connectome to account for loss of white matter nor updates the model to account for loss of αsyn that dead neurons once contained.

Uneven antibody penetrance between mice could potentially confound data. There are also limitations regarding our dataset because it is only semi-quantitative [34; 36]. However, in our long-term study [34], we performed densitometry analysis of psen129 inclusions on a restricted number of brain regions, in addition to our semi-quantitative analysis, and the results from both method were consistent indicating that our semi-quantitative analysis using scores reflects well the density of inclusions present in a given brain region. Finally, cellular inflammatory and excocytosis responses that occur in response to injection with α-synuclein fibrils could affect spread processes for α-synuclein inclusions at timepoints closest to injection. The fit of the DNT model at 3-months post-injection is worse than at any other timepoint, potentially indicating injection-response cellular processes as a limitation for how well a spread or diffusion model can fit data at timepoints close to injection.

Additionally of note, some technical aspects differs between the different datasets. We performed injections into the olfactory bulb in 7-8 weeks old C57/Bl6 mice, while Masuda-Suzukake and coworkers [25] injected older mice of the same strains. Regarding our intrastriatal injections, we injected 4 week-old mice of a different background strain (OF1 mice). The fibrils used for each dataset were different or produced by different labs: for olfactory bulb injections, mPFFs and huPFFs were produced by K. Luk while huPFFs used for striatal injections were produced in our lab (following K Luk’s published protocol) [50]; and Masuda-Suzukake’s fibrils were produced following a different protocol in their own lab [25]. Thus, it is possible that these
different assemblies have different seeding and propagation capacities. Despite these differences, our results demonstrate similar propagation characteristics in the three different datasets.

**Concluding remarks.** In conclusion, we provide evidence that the propagation of synucleinopathy in fibril-injection mouse models occurs via neural network and transsynaptically. Our findings in mice support the hypothesis by Braak and colleagues of propagation of αsyn pathology via neuronal networks in humans [4; 5; 6; 7; 8; 15]. In addition, we demonstrate that the preferred direction of αsyn inclusions propagation is initially retrograde, and becomes anterograde at several months post injection, indicating that the preferred direction can switch over time.

**Acknowledgements:**
We acknowledge the Van Andel Research Institute and the many individuals and corporations that financially support research into neurodegenerative disease at the Institute. N.L.R.’s work is supported by the Peter C. and Emajean Cook Foundation. P.B. is supported by grants from the National Institutes of Health (1R01DC016519-01, 5R21NS093993-02 and 1R21NS106078-01A1). P.B. reports additional grants from Office of the Assistant Secretary of Defense for Health Affairs (Parkinson’s Research Program, Award No. W81XWH-17-1-0534), The Michael J Fox Foundation, National Institutes of Health, Cure Parkinson’s Trust, which are outside but relevant to the submitted work.

We would also like to acknowledge the Weill Cornell Neuroscience and Radiology Departments, as well as the Feil Family Brain & Mind Research Institute and the many people who generously support Weill Cornell. AR and CM are supported by grants from the National
Institutes of Health (R01NS092802). AR and CM would also like to acknowledge our former and present colleagues from the IDEAL lab.

We also thank Luk, KC, Trojanowski, JQ, Lee, VM, George, S, Steiner, JA, Madaj Z, Maroof, N, Chatterjee N, Saiz Sanchez D, Quansah E, Becker K, Ma J, Escobar Galvis ML, Kordower JH for the fruitful collaboration which led us to the three prior publications from which we have extracted data for the current study.

Compliance with ethical standards

Conflict of interest

P.B. has received commercial support as a consultant from Renovo Neural, Inc., Roche, and Teva Inc, Lundbeck A/S, AbbVie, Neuroderm, Fujifilm-Cellular Dynamics, ClearView Healthcare, FCB Health, IOS Press Partners and Capital Technologies, Inc. P.B. has received commercial support for grants/research from Renovo and Teva/Lundbeck. P.B. has ownership interests in Acousort AB and is on the steering committee of the NILO-PD trial.

The authors declare no additional competing financial interests.

Ethical approval and consent to participate.

All mouse-work datasets in the present work was obtained from datasets originally intended and used for other already published work already declaring that all animal work was done under approved protocols and animal care standards [25; 34; 36].
Data Availability Statement

All primary data cited in the present manuscript is already available for access from citations [12; 25; 33; 34; 35; 36; 37].

References

1. Angot E, Steiner JA, Hansen C, Li J, Brundin P. Are synucleinopathies prion-like disorders? *Lancet Neurol.* 2010;9:1128-1138. doi:10.1016/S1474-4422(10)70213-1.

2. Beach TG, Adler CH, Lue L, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. *Acta Neuropathol.* 2009;117:613-634. doi:10.1007/s00401-009-0538-8.

3. Bieri G, Gitler AD, Brahic M. Internalization, axonal transport and release of fibrillar forms of alpha-synuclein. *Neurobiol Dis.* 2018;109:219-225.

4. Braak H, Rüb U, Gai WP, Tredici K Del. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. *J Neural Transm.* 2003;110:517-536. doi:10.1007/s00702-002-0808-2.

5. Braak H, Del K, Rüb U, Vos RAI De, Jansen ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. *Neurobiol Aging.* 2003;24:197-211.

6. Braak H, Tredici K Del. Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff. *J Parkinsons Dis.* 2017;7:571-585. doi:10.3233/JPD-179001.

7. Braak H, Tredici K Del. Potential Pathways of Abnormal Tau and alpha-Synuclein Dissemination in Sporadic Alzheimer’s and Parkinson’s Diseases. *Cold Spring Harb Perspect Biol.* 2016:1-24.

8. Braak RH, Ghebremedhin E, Rüb U, Bratzke H, Tredici K Del. Stages in the development of Parkinson’s disease-related pathology. *Cell Tissue Res.* 2004;318:121-134. doi:10.1007/s00441-004-0956-9.

9. Brettschneider J, Del Tredici K, Lee VM-Y, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. *Nat Rev Neurosci.* 2015;16(2):109-120. doi:10.1038/nrn3887.Spreading.

10. Brundin P, Li J, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson’s disease pathology spread. *Nat Rev Neurosci.* 2008;9(October):741-745.
11. Brundin P, Melki R. Prying into the Prion Hypothesis for Parkinson’s Disease. *J Neurosci*. 2017;37(41):9808-9818. doi:10.1523/JNEUROSCI.1788-16.2017.

12. Chatterjee D, Saiz Sanchez D, Quansah E, et al. Loss of one Engrailed1 allele enhances induced α-synucleinopathy. *J Parkinson’s Dis*. 2019; 9(2): 315-326 January(26th). doi: 10.3233/JPD-191590.

13. Dehay B, Fernagut P. Alpha-synuclein based models of Parkinson’s disease. *Rev Neurol (Paris)*. 2016;172(6-7):371-378.

14. Dehay B, Vila M, Bezard E, Brundin P, Kordower J. Alpha-synuclein propagation: New insights from animal models. *Mov Disord*. 2016;31(2):161-168.

15. Del Tredici K, Braak H. Review: Sporadic Parkinson’s disease: development and distribution of alpha-synuclein pathology. *Neuropathol Appl Neurobiol*. 2016;42:33-50. doi:10.1111/nan.12298.

16. Freeze B, Acosta D, Pandya S, Zhao Y, Raj A. Regional expression of genes mediating trans-synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. *NeuroImage Clin*. 2018;18:456-466.

17. Freundt EC, Maynard N, Clancy EK, et al. Neuron-to-Neuron Transmission of alpha-Synuclein Fibrils Through Axonal Transport. *Ann Neurol*. 2012;72:517-524. doi:10.1002/ana.23747.

18. Goedert M. Alpha-synuclein and neurodegenerative diseases. *Nat Rev Neurosci*. 2001;2(July):492-501.

19. Goedert M, Jakes R, Spillantini MG. The Synucleinopathies: Twenty Years On. *J Parkinsons Dis*. 2017;7:551-569. doi:10.3233/JPD-179005.

20. Grozdanov V, Danzer KM. Release and uptake of pathologic alpha-synuclein. *Cell Tissue Res*. 2018;373:175-182.

21. Hawkes CH, Tredici K Del, Braak H, Wolfgang J, Main F. Review: Parkinson’s disease: a dual-hit hypothesis. *Neuropathol Appl Neurobiol*. 2007;33:599-614. doi:10.1111/j.1365-2990.2007.00874.x.

22. Henderson, MX, Cornblath, EJ, Darwich, A, Zhang, B, Brown, H, et al. Spread of alpha-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. *Nature Neuroscience*. 2019; 22: 1248-1257.

23. Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science (80- ).* 2012;338(16 November 2012):949-953. doi:10.1126/science.1227157.
24. Luk KC, Lee VM. Modeling Lewy pathology propagation in Parkinson’s disease. *Park Relat Disord*. 2014;20(0 1):S85-S87. doi:10.1016/S1353-8020(13)70022-1.

25. Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Prion-like spreading of pathological alpha-synuclein in brain. *Brain*. 2013;136(July):1128-1138. doi:10.1093/brain/awt037.

26. Mezias C, LoCastro E, Xia C, Raj A. Connectivity, not region-intrinsic properties, predicts regional vulnerability to progressive tau pathology in mouse models of disease. *Acta Neuropathol Commun*. 2017;5(61):1-17. doi:10.1186/s40478-017-0459-z.

27. Mezias C, Raj A. Analysis of Amyloid-β Pathology Spread in Mouse Models Suggests Spread Is Driven by Spatial Proximity, Not Connectivity. *Front Neurol*. 2017;8(December):1-12. doi:10.3389/fneur.2017.00653.

28. Oh SW, Harris JA, Ng L, et al. A mesoscale connectome of the mouse brain. *Nature*. 2014;508(10 April):207-214. doi:10.1038/nature13186.

29. Paxinos G, Franklin K. *Paxinos & Franklin’s: The Mouse Brain in Stereotaxic Coordinates*. 4th ed. Academic Press; 2012.

30. Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. *Neuron*. 2012;73(6):1204-1215. doi:10.1016/j.

31. Raj A, Locastro E, Kuceyeski A, Tosun D, Relkin N, Weiner M. Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer’s Disease. *Cell Rep*. 2015;10(January 20):359-369.

32. Recasens A, Ulusoy A, Kahle PJ, Monte DA Di, Dehay B. In vivo models of alpha-synuclein transmission and propagation. *Cell Tissue Res*. 2018;373:183-193.

33. Rey NL, George S, Brundin P. Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein. *Neuropathol Appl Neurobiol*. 2016;42:51-76. doi:10.1111/nan.12299.

34. Rey NL, George S, Steiner JA, et al. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term. *Acta Neuropathol*. 2018;135:65-83.

35. Rey NL, Petit GH, Bousset L, Melki R, Brundin P. Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice. *Acta Neuropathol*. 2013;126:555-573. doi:10.1007/s00401-013-1160-3.

36. Rey NL, Steiner JA, Maroof N, et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. *J Exp Med*. 2016;8 August:1-20. doi:10.1084/jem.20160368.
37. Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. *Neurobiol Dis*. 2018;109(January 2018):226-248. doi:10.1016/j.nbd.2016.12.013.

38. Rusconi R, Ulusoy A, Aboutalebi H, Di DA. Long-lasting pathological consequences of overexpression-induced alpha-synuclein spreading in the rat brain. *Aging Cell*. 2018;17:1-11. doi:10.1111/acel.12727.

39. Saha AR, Hill J, Utton MA, et al. Parkinson’s disease α-synuclein mutations exhibit defective axonal transport in cultured neurons. *J Cell Sci*. 2004;117(7):1017-1024. doi:10.1242/jcs.00967.

40. Steiner JA, Angot E, Brundin P. A deadly spread: cellular mechanisms of alpha-synuclein transfer. *Cell Death Differ*. 2011;18:1425-1433. doi:10.1038/cdd.2011.53.

41. Surmeier DJ, Obeso A, Halliday XGM. Parkinson’s Disease Is Not Simply a Prion Disorder. *J Neurosci*. 2017;37(41):9799-9807. doi:10.1523/JNEUROSCI.1787-16.2017.

42. Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. *Nat Rev Neurosci*. 2017;18(February):101-113. doi:10.1038/nrn.2016.178.

43. Tang Y, Das U, Scott DA, Roy S. The Slow Axonal Transport of Alpha-Synuclein—Mechanistic Commonalities Amongst Diverse Cytosolic Cargoes. *Cytoskeleton*. 2012;69(July):506-513. doi:10.1002/cm.21019.

44. Tyson T, Steiner JA, Brundin P. Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. *J Neurochem*. 2016;139:275-289. doi:10.1111/jnc.13449.

45. Ubeda-Bañon I, Saiz-Sanchez D, de la Rosa-Prieto C, Martinez-Marcos A. Alpha-Synuclein in the olfactory system in Parkinson’s disease: role of neural connections on spreading pathology. *Brain Struct Funct*. 2014;219:1513-1526. doi:10.1007/s00429-013-0651-2.

46. Uchihara T, Giasson BI. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. *Acta Neuropathol*. 2016;131:49-73. doi:10.1007/s00401-015-1485-1.

47. Ulusoys RJ, Phillips RJ, Helwig M, Klinkenberg M, Powley TL, DiMonte DA. Brain-to-stomach transfer of alpha-synuclein via vagal preganglionic projections. *Acta Neuropathol*. 2017;133(3):381-393. doi:10.1007/s00401-016-1661-y.

48. Ulusoy A, Rusconi R, Pérez-Revuelta BI, et al. Caudo-rostral brain spreading of alpha-synuclein through vagal connections. *EMBO Mol Med*. 2013;5:1119-1127. doi:10.1002/emmm.201302475.
49. Utton MA, Noble WJ, Hill JE, Anderton BH, Hanger DP. Molecular motors implicated in the axonal transport of tau and alpha-synuclein. *J Cell Sci.* 2005;118(20):4645-4654. doi:10.1242/jcs.02558.

50. Volpicelli-Daley L, Luk KC, Lee VM. Addition of exogenous alpha-synuclein pre-formed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. *Nat Protoc.* 2015;9(9):2135-2146. doi:10.1038/nprot.2014.143.Addition.

51. Volpicelli-Daley LA. Effects of α-synuclein on axonal transport. *Neurobiol Dis.* 2017;105:321-327.

52. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-Synuclein fibrils induce Lewy Body pathology leading to synaptic dysfunction and neuron death. *Neuron.* 2011;72(1):57-71. doi:10.1016/j.neuron.2011.08.033.Exogenous.
Figure legends

**Figure 1.** Anatomical example of network transmission, what the DNT model represents, and how to assess it. (a) α-Syn fibrils can be internalized both in the dendrite/cell body compartment and in axons. α-Syn fibrils are actively transported along microtubules both in the anterograde (driven by kinesin) and retrograde (driven by dynein) direction, perhaps directly in the cytoplasm or perhaps in transport vesicles following endocytosis. Aggregation is thought to initially occur in axons, where α-syn fibrils can encounter and template the misfolding of soluble endogenous α-syn proteins that are transported along axons for delivery to synapses. Figure adapted with permission from Bieri, et al., 2018. (b) Graphic illustration of the whole brain directional connectivity network, with nodes representing brain regions, and connection strengths \{Cij\} representing tracer-derived mesoscale connectivity. Examples of anterograde and retrograde transmission on this network are depicted. This macroscopic network transmission model is driven by the cellular-level transmission and transport processes depicted in panel A. (c) Example of a βt-curve showing r-value across βt parameter values for predictive (peak at βt > 0) and non-predictive models (peak at βt = 0). (d) A color legend and brain showing the color scheme, by major region, for all the balls depicting regions in all anatomical illustrations of mouse brains throughout the rest of the paper. The dot sizes correspond to randomly generated “example” or “pseudo” inclusions amounts, per-region, where each dot represents one region in its center of mass. In anatomic illustrations of this nature with actual results, the inclusions amounts will not be random, but will rather be determined by inclusions severity recorded from data or predicted by a given NT model.

**Figure 2.** Synuclein inclusion spread is better modeled by retrograde DNT at early timepoints, and anterograde DNT at later timepoints. (a) βt-curve showing NT models’ r-value with mPFF data at 3-months post-injection at different diffusion time constants. (b) Scatterplot of the NT models at their peak β-diffusion time constant, as in (a) to the left, versus data. (c) Anatomical illustrations of mPFF synuclein inclusion data and DNT-retrograde simulation. (d) βt-curve showing NT models’ r-value with mPFF data at 12-months post-injection at different diffusion time constants. (e) Scatterplot of the NT models at their peak β-diffusion time constant, as in (d) to the left, versus data. (f) Anatomical illustrations of mPFF induced synuclein inclusions at 12 months post injection and the corresponding anterograde-DNT simulation. AMY = amygdala, AOB = accessory olfactory bulb, AON = anterior olfactory nucleus, DG = dentate gyrus, ENT = entorhinal cortex, MOB = main olfactory bulb, PIR = piriform cortex, SUB = subiculum, TT = tenia tecta. Please see Figure 1 for color legend for the major region color scheme of the balls denoting regional αsyn inclusions. The red arrow points toward the MOB where the PFFs were injected. Significance level: + p < 0.01, * p < 0.02

**Figure 3.** Synuclein inclusion spread is better modeled by retrograde DNT at early timepoints, and anterograde DNT at later timepoints. (a) βt-curve showing NT models’ r-value with huPFF data at 3-months post-injection at different diffusion time constants. (b) Scatterplot of the NT models at their peak β-diffusion time constant, as in (a) to the left, versus data. (c) Anatomical illustrations of huPFF synuclein inclusion data and DNT-retrograde simulation. (d) βt-curve showing NT models’ r-value with huPFF data at 12-months post-injection at different diffusion time constants. (e) Scatterplot of the NT models at their peak β-diffusion time constant, as in (d) to the left, versus data. (f) Anatomical illustrations of huPFF induced synuclein inclusions at 12
months post injection and the corresponding anterograde-DNT simulation. All data and NT simulation values are log-transformed prior to both statistics and anatomical visualizations.

AMY = amygdala, AOB = accessory olfactory bulb, AON = anterior olfactory nucleus, DG = dentate gyrus, ENT = entorhinal cortex, MOB = main olfactory bulb, PIR = piriform cortex, SUB = subiculum, TT = tenia tecta. Please see Figure 1 for color legend for the major region color scheme of the balls denoting regional αsyn inclusions. The red arrow points toward the MOB where the PFFs were injected. + p < 0.01, * p < 0.02

**Figure 4.** At 18-months post injection, we find the same phenomenon of strong inclusion pattern recreation by our anterograde DNT model at timepoints far from injection, and in contrast with findings at earlier measured timepoints. (a) βt-curve showing NT models’ r-value with huPFF data at 18-months post-injection at different diffusion time constants, (b) Scatterplots for each model’s prediction at the βt diffusion rate constant that maximizes r-values with regional αsyn inclusion data from huPFF injected mice. (c) An anatomical illustration of regional αsyn inclusion pattern data and anterograde and retrograde DNT model predictions for huPFF injected mice. (d) βt-curve showing NT models’ r-value with mPFF data at 18-months post-injection at different diffusion time constants. (e) Scatterplots for each model’s prediction at the βt diffusion rate constant that maximizes r-values with regional αsyn inclusion data from mPFF injected mice. (f) An anatomical illustration of regional αsyn inclusion pattern data and anterograde and retrograde DNT model predictions for mPFF injected mice. AMY = amygdala, AOB = accessory olfactory bulb, AON = anterior olfactory nucleus, DG = dentate gyrus, ENT = entorhinal cortex, MOB = main olfactory bulb, NAcc = nucleus accumbens, PIR = piriform cortex, SUB = subiculum, TT = tenia tecta. Please see Figure 1 for color legend for the major region color scheme of the balls denoting regional αsyn inclusions. The red arrow points toward the MOB where the PFFs were injected. + p < 0.01, * p < 0.02

**Figure 5.** DNT retrograde models are better predictors of synuclein inclusions closer to initial pathological injection, but anterograde DNT is a better predictor of synuclein inclusions as more time elapses following injection. (a) mPFF synuclein injected mice and (b) huPFF synuclein injected mice both show spatiotemporal synucleinopathy development such that at times closer to the initial injection, retrograde DNT is the best predictor, but at times farther from the injection, anterograde DNT better recapitulates αsyn inclusion spread than does retrograde DNT. (c) Calculated directional bias in the fit with data between anterograde and retrograde DNT models shifts towards anterograde DNT over time. A reference line at 0, the value at which there should be no directional bias, is added to the plot in (c). All data and NT simulation values are log-transformed prior to running statistics.

**Figure 6.** Datasets using other injection sites show the same directional shift as our data: that at timepoints surrounding the injection, synuclein inclusions are better explained by a model positing retrograde spread, but at timepoints farther from the injection, models using anterograde spread perform better. (a) Another dataset from Patrik Brundin’s lab [12] using mice injected with fibrils into the striatum with regional quantification at 8-weeks post injection show the same pattern, regardless of genotype, as this early post-injection quantification of αsyn inclusions is best fit by retrograde DNT. The next panels (b,c, d) use data from [24]: (b) Anterograde bias,
calculated as in the y-axis legend above is strongest at 15-months post injection, implying that anterograde DNT, relative to retrograde DNT, performs better at later timepoints, across both ours and the Masuda-Suzukake, et al. 2013 study. A reference line at 0, the value at which there should be no directional bias, is added to the plot in (b). (c) An example, from Masuda-Suzukake, et al., 2013, showing the same switch from synuclein inclusions being best recreated by retrograde DNT at early timepoints, to being best recapitulated by anterograde DNT at later timepoints. (d) An anatomic illustration of the data and DNT simulated data from Masuda-Suzukake, et al. 2013, as in (b) & (c) above. All data and NT simulation values are log-transformed prior to running correlations. + p < 0.01, * p < 0.02
Highlights

- Mathematically modeling αsyn spread along fiber tracts recreates inclusions patterns.
- Modeled retrograde (post-to-presynaptic) spread best recreates early inclusions patterns.
- Modeled anterograde (pre-to-postsynaptic) spread better fits later inclusions pattern.
- Overall results indicate a potential directional switch in αsyn spread over time.
- All above results are consistent across multiple, independently collected, datasets.
Figure 1
Figure 4

(a) huPFFs Vs. DNT

(b) Correlation plots for huPFFs and DNT

(c) Data representations for different brain areas

(d) mPFFs Vs. DNT

(e) Correlation plots for mPFFs and DNT

(f) Additional data representations for different brain areas
Figure 6

Data from Brundin Lab

Max R-Val. Per Mouse

Ant. DNT Ret. DNT

p < 0.002

bond directional spread bias over time

Bias ($\Delta R_{\text{ANT}} - \Delta R_{\text{RET}})$

Time in Months

3 6 15

Example $\Delta R$ Over Time, Masuda-Suzukake et al.

Time (Months)

3 6 15

Data

Month 3

Month 15

DNT Ant.

DNT Ret.